Evidence map›Paper›PMID 26322584›Full record

ArticleNature2015

η-Secretase processing of APP inhibits neuronal activity in the hippocampus.

Michael Willem, Sabina Tahirovic, Marc Aurel Busche, Saak V Ovsepian, Magda Chafai, Scherazad Kootar, Daniel Hornburg, Lewis D B Evans, Steven Moore, Anna Daria and 17 more

Open access · greenAbstract read
In one paragraph

Article in Nature, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 202 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
202citing papers in PubMed, 2 pooled it
27.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

202 citing papers in PubMed, 2 syntheses or guidelines pooled it, 364 citations in OpenAlex.

  1. Genetic and environmental risk factors for dementia in African adults: A systematic review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Early involvement of D-serine in β-amyloid-dependent pathophysiology.Cellular and molecular life sciences : CMLS · 2025
    Article
  17. Article
  18. Article
  19. Review
  20. Frontiers in neuroscience · 2025
    Article

142 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 13 institutions in 5 countries.

Michael WillemBiomedical Center (BMC), Ludwig-Maximilians-University Munich, 81377 Munich, Germany.
Sabina TahirovicGerman Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany.
Marc Aurel BuscheDepartment of Psychiatry and Psychotherapy, Technische Universität München, 81675 Munich, Germany.
Saak V OvsepianGerman Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany.
Magda ChafaiInstitut de Pharmacologie Moléculaire et Cellulaire (IPMC), Centre National de la Recherche Scientifique (CNRS), Université de Nice Sophia Antipolis, UMR 7275, 06560 Valbonne, France.
Scherazad KootarInstitut de Pharmacologie Moléculaire et Cellulaire (IPMC), Centre National de la Recherche Scientifique (CNRS), Université de Nice Sophia Antipolis, UMR 7275, 06560 Valbonne, France.
Daniel HornburgMax Planck Institute of Biochemistry, Martinsried 82152, Germany.
Lewis D B EvansGurdon Institute, Cambridge Stem Cell Institute &Department of Biochemistry, University of Cambridge, Cambridge CB2 1QN, UK.
Steven MooreGurdon Institute, Cambridge Stem Cell Institute &Department of Biochemistry, University of Cambridge, Cambridge CB2 1QN, UK.
Anna DariaBiomedical Center (BMC), Ludwig-Maximilians-University Munich, 81377 Munich, Germany.
Heike HampelBiomedical Center (BMC), Ludwig-Maximilians-University Munich, 81377 Munich, Germany.
Veronika MüllerBiomedical Center (BMC), Ludwig-Maximilians-University Munich, 81377 Munich, Germany.
Camilla GiudiciBiomedical Center (BMC), Ludwig-Maximilians-University Munich, 81377 Munich, Germany.
Brigitte NuscherBiomedical Center (BMC), Ludwig-Maximilians-University Munich, 81377 Munich, Germany.
Andrea Wenninger-WeinzierlGerman Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany.
Elisabeth KremmerGerman Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany.
Michael T HenekaDepartment of Neurology, Clinical Neuroscience Unit, University of Bonn, 53127 Bonn, Germany.
Dietmar R ThalInstitute of Pathology - Laboratory for Neuropathology, University of Ulm, 89081 Ulm, Germany.
Vilmantas GiedraitisDepartment of Public Health/Geriatrics, Uppsala University, 751 85 Uppsala, Sweden.
Lars LannfeltDepartment of Public Health/Geriatrics, Uppsala University, 751 85 Uppsala, Sweden.
Ulrike MüllerInstitute for Pharmacy and Molecular Biotechnology IPMB, Functional Genomics, University of Heidelberg, 69120 Heidelberg, Germany.
Frederick J LiveseyGurdon Institute, Cambridge Stem Cell Institute &Department of Biochemistry, University of Cambridge, Cambridge CB2 1QN, UK.
Felix MeissnerMax Planck Institute of Biochemistry, Martinsried 82152, Germany.
Jochen HermsGerman Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany.
Arthur KonnerthInstitute of Neuroscience, Technische Universität München, 80802 Munich, Germany.
Hélène MarieInstitut de Pharmacologie Moléculaire et Cellulaire (IPMC), Centre National de la Recherche Scientifique (CNRS), Université de Nice Sophia Antipolis, UMR 7275, 06560 Valbonne, France.
Christian HaassBiomedical Center (BMC), Ludwig-Maximilians-University Munich, 81377 Munich, Germany.
Ludwig-Maximilians-Universität München · DEGerman Center for Neurodegenerative Diseases · DEInstitut de Pharmacologie Moléculaire et Cellulaire · FRMax Planck Institute of Biochemistry · DEUppsala University · SECentre National de la Recherche Scientifique · FRFrauenklinik der Technischen Universität München · DEHeidelberg University · DETechnical University of Munich · DEUniversität Ulm · DEUniversity of Cambridge · GBWellcome/Cancer Research UK Gurdon Institute · GBWellcome/MRC Cambridge Stem Cell Institute · GB

Funding

Medical Research Council MR/L023784/1Medical Research Council MR/L023784/2Wellcome Trust 101052
6 · The paper itself

Abstract

Alzheimer disease (AD) is characterized by the accumulation of amyloid plaques, which are predominantly composed of amyloid-β peptide. Two principal physiological pathways either prevent or promote amyloid-β generation from its precursor, β-amyloid precursor protein (APP), in a competitive manner. Although APP processing has been studied in great detail, unknown proteolytic events seem to hinder stoichiometric analyses of APP metabolism in vivo. Here we describe a new physiological APP processing pathway, which generates proteolytic fragments capable of inhibiting neuronal activity within the hippocampus. We identify higher molecular mass carboxy-terminal fragments (CTFs) of APP, termed CTF-η, in addition to the long-known CTF-α and CTF-β fragments generated by the α- and β-secretases ADAM10 (a disintegrin and metalloproteinase 10) and BACE1 (β-site APP cleaving enzyme 1), respectively. CTF-η generation is mediated in part by membrane-bound matrix metalloproteinases such as MT5-MMP, referred to as η-secretase activity. η-Secretase cleavage occurs primarily at amino acids 504-505 of APP695, releasing a truncated ectodomain. After shedding of this ectodomain, CTF-η is further processed by ADAM10 and BACE1 to release long and short Aη peptides (termed Aη-α and Aη-β). CTFs produced by η-secretase are enriched in dystrophic neurites in an AD mouse model and in human AD brains. Genetic and pharmacological inhibition of BACE1 activity results in robust accumulation of CTF-η and Aη-α. In mice treated with a potent BACE1 inhibitor, hippocampal long-term potentiation was reduced. Notably, when recombinant or synthetic Aη-α was applied on hippocampal slices ex vivo, long-term potentiation was lowered. Furthermore, in vivo single-cell two-photon calcium imaging showed that hippocampal neuronal activity was attenuated by Aη-α. These findings not only demonstrate a major functionally relevant APP processing pathway, but may also indicate potential translational relevance for therapeutic strategies targeting APP processing.

Indexed as

ProteolysisADAM10 ProteinADAM ProteinsAlzheimer DiseaseAmyloid beta-Protein PrecursorAmyloid Precursor Protein SecretasesAnimalsAspartic Acid EndopeptidasesCalcium SignalingDisease Models, AnimalFemaleHippocampusHumansIn Vitro TechniquesLong-Term PotentiationMaleADAM10 ProteinADAM10 protein, humanADAM ProteinsAmyloid beta-Protein PrecursorAmyloid Precursor Protein SecretasesAPP protein, humanAspartic Acid EndopeptidasesBACE1 protein, humanBace1 protein, mouseMatrix Metalloproteinases, Membrane-AssociatedMembrane ProteinsMmp24 protein, mousePeptide Fragments

Identifiers

PMID26322584
PMCPMC6570618
OpenAlexW1779570864

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.